Camp4 Therapeutics Targets IPO On Early Positive Results
Camp4 Therapeutics is seeking $75 million in its IPO to advance clinical-stage programs. Learn more about CAMP stock and ...
Medscape2d
Not So Rare: Errors of Metabolism During the Neonatal Period
Sandra A. Banta-Wright, MN, RNC, NNP; Robert D. Steiner, MD Neonates with profound and prolonged hyperammonemia with coma due to urea cycle defect will have had a neurological insult to the brain ...
Hosted on MSN1d
Diet-derived molecules identified as main drivers of young-onset colorectal cancer risk
Younger colon cancer patients had higher levels of metabolites associated with the production and metabolism of an amino acid called arginine, and with the urea cycle compared to their older peers.
FierceBiotech2d
CAMP4, BioMarin ink research deal for genetic disease targets
BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets ...
Unlock The Secrets Of Genetics With PNRI's New Podcast: PNRI Science: Mystery And Discovery
Jack Faris interviews PNRI's brilliant scientists to uncover what excites them about genetic research, what inspired their ...
Neuroscience News3d
New Astrocyte Target for Alzheimer’s Therapy
Researchers have identified a novel therapeutic target for Alzheimer’s disease by focusing on astrocytes, non-neuronal brain cells involved in waste removal.